Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Pacific Biosciences of California stock price, quote, forecast and news

PACB
US69404D1081
A1C3EQ

Price

1.62
Today +/-
+0
Today %
+0 %
P

Pacific Biosciences of California Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Pacific Biosciences of California, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Pacific Biosciences of California from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Pacific Biosciences of California’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Pacific Biosciences of California. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Pacific Biosciences of California’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Pacific Biosciences of California’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Pacific Biosciences of California’s growth potential.

Pacific Biosciences of California Revenue, EBIT and net profit per share

DatePacific Biosciences of California RevenuePacific Biosciences of California EBITPacific Biosciences of California Net Income
2029e612.05 M undefined0 undefined-8.33 M undefined
2028e441.02 M undefined-73.01 M undefined-83.34 M undefined
2027e386.64 M undefined-121.81 M undefined-105.57 M undefined
2026e330.87 M undefined-164.76 M undefined-153.07 M undefined
2025e244.82 M undefined-207.53 M undefined-203.1 M undefined
2024e183.94 M undefined-259.46 M undefined-254.59 M undefined
2023200.52 M undefined-321.99 M undefined-306.74 M undefined
2022128.3 M undefined-303.5 M undefined-314.2 M undefined
2021130.5 M undefined-179.3 M undefined-181.2 M undefined
202078.9 M undefined-104.4 M undefined29.4 M undefined
201990.9 M undefined-100.5 M undefined-84.1 M undefined
201878.6 M undefined-101 M undefined-102.6 M undefined
201793.5 M undefined-89.8 M undefined-92.2 M undefined
201690.7 M undefined-71.2 M undefined-74.4 M undefined
201592.8 M undefined-52.1 M undefined-31.7 M undefined
201460.6 M undefined-62.9 M undefined-66.2 M undefined
201328.2 M undefined-77.5 M undefined-79.3 M undefined
201226 M undefined-94.3 M undefined-94.5 M undefined
201133.9 M undefined-109.8 M undefined-109.4 M undefined
20101.7 M undefined-140.2 M undefined-140.2 M undefined
2009100,000 undefined-88.1 M undefined-87.7 M undefined
2008900,000 undefined-44.8 M undefined-43.8 M undefined
20072.2 M undefined-23.4 M undefined-21.5 M undefined
20062 M undefined-11.9 M undefined-11.7 M undefined
20051.4 M undefined-10.9 M undefined-10.9 M undefined

Pacific Biosciences of California Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
12200133262860929093789078130128200183244330386441612
-100.00----3,200.00-21.217.69114.2953.33-2.173.33-16.1315.38-13.3366.67-1.5456.25-8.5033.3335.2516.9714.2538.78
-----100.0039.39-21.4338.3357.6148.8936.5632.0537.7841.0344.6240.6328.00------
000001130623534434253432585256000000
-10-11-23-44-88-140-109-94-77-62-52-71-89-101-100-104-179-303-321-259-207-164-121-730
-1,000.00-550.00-1,150.00---14,000.00-330.30-361.54-275.00-103.33-56.52-78.89-95.70-129.49-111.11-133.33-137.69-236.72-160.50-141.53-84.84-49.70-31.35-16.55-
-10-11-21-43-87-140-109-94-79-66-31-74-92-102-8429-181-314-306-254-203-153-105-83-8
-10.0090.91104.76102.3360.92-22.14-13.76-15.96-16.46-53.03138.7124.3210.87-17.65-134.52-724.1473.48-2.55-16.99-20.08-24.63-31.37-20.95-90.36
50.150.150.150.150.152.953.955.762.870.575.689.1105.7135.1152.5175204.1224.6253.63000000
-------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Pacific Biosciences of California Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Pacific Biosciences of California is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Pacific Biosciences of California provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Pacific Biosciences of California's financial health and stability.

Assets

Pacific Biosciences of California's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Pacific Biosciences of California must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Pacific Biosciences of California after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Pacific Biosciences of California's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20072008200920102011201220132014201520162017201820192020202120222023
-21-43-87-140-109-94-79-66-31-74-92-102-8429-181-314-306
1245565433877671019
00000000000000-930-11
1042-121330-31-18-65-3-221-53-58
347192419192125404246173208173170
0000001111111061415
00000000000000000
-16-38-74-122-102-76-29-51-47-67-67-66-7819-111-263-259
-3-5-5-5-9-10-1-3-8-10-1-2-1-5-16-8
-18-1018-138661-33198-14-1-3862-219-6781164
-15-423-1321563-322111-68-3664-218-67213313
00000000000000000
00-100019000-400-16895-1-1
012068318722341366573107823332611204
00.120.070.320.0100.040.040.040.070.070.110.030.251.170.010.11
0000000000001834-520-93
00000000000000000
-35711058-88-12-2010-2-16021052379-137-145
-19.78-44-80.02-127.26-112.25-78.52-30.74-53.08-50.9-76.14-77.95-68.28-81.1518.46-117.11-280.14-268.02
00000000000000000

Pacific Biosciences of California stock margins

The Pacific Biosciences of California margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Pacific Biosciences of California. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Pacific Biosciences of California.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Pacific Biosciences of California's sales revenue. A higher gross margin percentage indicates that the Pacific Biosciences of California retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Pacific Biosciences of California's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Pacific Biosciences of California's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Pacific Biosciences of California's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Pacific Biosciences of California. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Pacific Biosciences of California's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Pacific Biosciences of California Margin History

Pacific Biosciences of California Gross marginPacific Biosciences of California Profit marginPacific Biosciences of California EBIT marginPacific Biosciences of California Profit margin
2029e28.03 %0 %-1.36 %
2028e28.03 %-16.55 %-18.9 %
2027e28.03 %-31.5 %-27.3 %
2026e28.03 %-49.79 %-46.26 %
2025e28.03 %-84.77 %-82.96 %
2024e28.03 %-141.06 %-138.41 %
202328.03 %-160.58 %-152.97 %
202241.08 %-236.55 %-244.89 %
202145.13 %-137.39 %-138.85 %
202041.32 %-132.32 %37.26 %
201938.06 %-110.56 %-92.52 %
201831.93 %-128.5 %-130.53 %
201737.11 %-96.04 %-98.61 %
201648.73 %-78.5 %-82.03 %
201557.65 %-56.14 %-34.16 %
201438.61 %-103.8 %-109.24 %
201322.7 %-274.82 %-281.21 %
20123.46 %-362.69 %-363.46 %
201138.35 %-323.89 %-322.71 %
2010100 %-8,247.06 %-8,247.06 %
2009100 %-88,100 %-87,699.99 %
200828.03 %-4,977.78 %-4,866.67 %
200728.03 %-1,063.64 %-977.27 %
200628.03 %-595 %-585 %
200528.03 %-778.57 %-778.57 %

Pacific Biosciences of California Stock Sales Revenue, EBIT, Earnings per Share

The Pacific Biosciences of California earnings per share therefore indicates how much revenue Pacific Biosciences of California has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Pacific Biosciences of California earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Pacific Biosciences of California's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Pacific Biosciences of California’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Pacific Biosciences of California's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Pacific Biosciences of California Revenue, EBIT and net profit per share

DatePacific Biosciences of California Sales per SharePacific Biosciences of California EBIT per sharePacific Biosciences of California Earnings per Share
2029e2.25 undefined0 undefined-0.03 undefined
2028e1.62 undefined0 undefined-0.31 undefined
2027e1.42 undefined0 undefined-0.39 undefined
2026e1.21 undefined0 undefined-0.56 undefined
2025e0.9 undefined0 undefined-0.75 undefined
2024e0.68 undefined0 undefined-0.93 undefined
20230.79 undefined-1.27 undefined-1.21 undefined
20220.57 undefined-1.35 undefined-1.4 undefined
20210.64 undefined-0.88 undefined-0.89 undefined
20200.45 undefined-0.6 undefined0.17 undefined
20190.6 undefined-0.66 undefined-0.55 undefined
20180.58 undefined-0.75 undefined-0.76 undefined
20170.88 undefined-0.85 undefined-0.87 undefined
20161.02 undefined-0.8 undefined-0.84 undefined
20151.23 undefined-0.69 undefined-0.42 undefined
20140.86 undefined-0.89 undefined-0.94 undefined
20130.45 undefined-1.23 undefined-1.26 undefined
20120.47 undefined-1.69 undefined-1.7 undefined
20110.63 undefined-2.04 undefined-2.03 undefined
20100.03 undefined-2.65 undefined-2.65 undefined
20090 undefined-1.76 undefined-1.75 undefined
20080.02 undefined-0.89 undefined-0.87 undefined
20070.04 undefined-0.47 undefined-0.43 undefined
20060.04 undefined-0.24 undefined-0.23 undefined
20050.03 undefined-0.22 undefined-0.22 undefined

Pacific Biosciences of California business model

Pacific Biosciences of California Inc is an American biotechnology company specializing in the development of systems for DNA sequencing and genome research. The company was founded in 2004 and is headquartered in Menlo Park, California. The company was founded by biochemist Stephen Turner, who had previously worked at Illumina, a leading company in genome research. The goal was to develop a new technology for DNA sequencing that would be faster and more accurate than existing systems. In 2005, the company received investments from notable venture capitalists such as Mohr Davidow Ventures, Alloy Ventures, and Kleiner Perkins Caufield & Byers. In 2010, Pacific Biosciences released its first commercial DNA sequencing system. The business model of Pacific Biosciences is based on the development and marketing of DNA sequencing systems and related products and services. The company offers standalone devices as well as integrated solutions for genome research to its customers, including research and diagnostic laboratories. Pacific Biosciences focuses on long-term customer relationships and the continuous advancement of its technologies. Pacific Biosciences operates in two main business segments: research and diagnostics. In the research segment, the company offers DNA sequencing systems that help researchers decipher the DNA of individual cells and complex genomes. These systems enable scientists to deepen their understanding of molecular-level biological processes and diseases. In the diagnostics segment, Pacific Biosciences develops solutions for personalized medicine and application in clinical laboratories. The main product of Pacific Biosciences is the PacBio RS II DNA sequencing platform. This system is based on the single-molecule sequencing technology, which offers high accuracy and reading speed. The PacBio RS II is a fully integrated device that performs both DNA preparation and sequencing, simplifying the entire workflow. In addition, Pacific Biosciences also offers a variety of products and services tailored to the needs of its customers. These include DNA extraction kits, sequencing software, and analysis tools. In summary, Pacific Biosciences of California is a biotechnology company specializing in the development of systems for DNA sequencing and genome research. Founded in 2004, the company is headquartered in Menlo Park, California. Pacific Biosciences operates in two main business segments, research and diagnostics, and offers a variety of products and services tailored to the needs of its customers. The main product of Pacific Biosciences is the PacBio RS II DNA sequencing platform, based on single-molecule sequencing technology. Pacific Biosciences of California is one of the most popular companies on Eulerpool.com.

Pacific Biosciences of California SWOT Analysis

Strengths

Pacific Biosciences of California Inc is known for its strong focus on technological innovation in the field of genetic sequencing. By developing cutting-edge sequencing platforms and technologies, the company has established itself as a leader in the industry, showcasing their ability to stay ahead of competitors.

The company boasts a robust intellectual property portfolio, which grants it a competitive advantage and protection against potential lawsuits or infringement claims. With a wide range of patents and exclusive rights, Pacific Biosciences of California Inc can safeguard its innovative discoveries and maintain a strong market position.

Weaknesses

One of the critical weaknesses of Pacific Biosciences of California Inc is its reliance on external funding sources. The company heavily depends on government grants and partnerships for research and development activities, which exposes it to potential funding uncertainties and limitations. This reliance on external sources can disrupt long-term planning and hinder the company's growth prospects.

Despite being a key player in the genetic sequencing industry, Pacific Biosciences of California Inc has a relatively limited market reach. The company primarily targets research institutions, academic organizations, and some pharmaceutical companies. Expanding their customer base beyond these segments could be a challenge and may restrict their revenue potential in other market sectors.

Opportunities

The increasing demand for genetic sequencing in various fields, including healthcare, agriculture, and biotechnology, presents a significant opportunity for Pacific Biosciences of California Inc. By capitalizing on this trend, the company can expand its customer base and increase revenue streams.

There is a potential for Pacific Biosciences of California Inc to form strategic partnerships with key players in related industries. Collaborating with pharmaceutical companies, diagnostic labs, or instrument manufacturers can provide access to new markets, enhance product offerings, and lead to mutually beneficial business opportunities.

Threats

Pacific Biosciences of California Inc faces intense competition from well-established competitors in the genetic sequencing market. The presence of companies with greater resources, market share, and brand recognition can pose a threat to the company's growth and market penetration efforts.

The genetic sequencing industry is subject to various regulatory and legal challenges, including compliance with data privacy laws, intellectual property disputes, and ethical considerations. Pacific Biosciences of California Inc must navigate these challenges carefully to avoid legal complications and maintain ethical practices.

Pacific Biosciences of California historical P/E ratio, EBIT, and P/S ratio.

Pacific Biosciences of California shares outstanding

The number of shares was Pacific Biosciences of California in 2023 — This indicates how many shares 253.629 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Pacific Biosciences of California earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Pacific Biosciences of California's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Pacific Biosciences of California’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Pacific Biosciences of California's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Pacific Biosciences of California.

Pacific Biosciences of California latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/2024-0.28 -0.29  (-3.24 %)2024 Q1
12/31/2023-0.29 -0.31  (-6.57 %)2023 Q4
9/30/2023-0.33 -0.26  (22.32 %)2023 Q3
6/30/2023-0.33 -0.28  (14.4 %)2023 Q2
3/31/2023-0.34 -0.36  (-6.13 %)2023 Q1
12/31/2022-0.37 -0.37  (-0.41 %)2022 Q4
9/30/2022-0.34 -0.34  (-0.5 %)2022 Q3
6/30/2022-0.33 -0.32  (2.97 %)2022 Q2
3/31/2022-0.31 -0.37  (-17.65 %)2022 Q1
12/31/2021-0.29 -0.31  (-7.27 %)2021 Q4
1
2
3
4
5
...
6

Eulerpool ESG Scorecard© for the Pacific Biosciences of California stock

Eulerpool World ESG Rating (EESG©)

40/ 100

🌱 Environment

10

👫 Social

59

🏛️ Governance

52

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Pacific Biosciences of California list of shareholders

%
Name
Stocks
Change
Date
9.82 % The Vanguard Group, Inc.26,740,6813,514,79212/31/2023
7.27 % BlackRock Institutional Trust Company, N.A.19,808,3972,231,60412/31/2023
6.46 % Madrone Advisors, LLC17,591,9151,175,98212/31/2023
4.71 % Nikko Asset Management Co., Ltd.12,824,385-375,9903/31/2024
3.86 % Morgan Stanley & Co. LLC10,504,6428,821,65212/31/2023
3.56 % Jackson Square Partners, LLC9,704,7662,770,90112/31/2023
2.85 % T. Rowe Price Investment Management, Inc.7,753,781338,25712/31/2023
2.69 % Bellevue Asset Management AG7,317,12871,94012/31/2023
2.57 % Deep Track Capital LP7,000,0001,000,00012/31/2023
2.27 % Farallon Capital Management, L.L.C.6,191,370-4,032,75012/31/2023
1
2
3
4
5
...
10

Pacific Biosciences of California Executives and Management Board

Mr. Christian Henry55
Pacific Biosciences of California President, Chief Executive Officer, Director (since 2018)
Compensation 6.62 M
Mr. Mark Van Oene50
Pacific Biosciences of California Chief Operating Officer
Compensation 6.56 M
Mr. Jeff Eidel46
Pacific Biosciences of California Chief Commercial Officer
Compensation 5.8 M
Ms. Susan Kim47
Pacific Biosciences of California Chief Financial Officer
Compensation 2.62 M
Dr. John Milligan62
Pacific Biosciences of California Independent Chairman of the Board
Compensation 296,998
1
2
3

Most common questions regarding Pacific Biosciences of California

What values and corporate philosophy does Pacific Biosciences of California represent?

Pacific Biosciences of California Inc represents a commitment to advancing scientific research and innovation in the field of biological sciences. With a strong focus on genetic sequencing technology, Pacific Biosciences is driven by the mission to enable groundbreaking discoveries and provide valuable insights into the complexity of biological systems. The company's corporate philosophy revolves around delivering high-quality, accurate, and scalable sequencing solutions that empower researchers and drive advancements in areas such as personalized medicine, agriculture, and conservation. Pacific Biosciences of California Inc aligns its values with transparency, collaboration, and a dedication to pushing the boundaries of scientific understanding through state-of-the-art technology and research.

In which countries and regions is Pacific Biosciences of California primarily present?

Pacific Biosciences of California Inc is primarily present in the United States of America.

What significant milestones has the company Pacific Biosciences of California achieved?

Pacific Biosciences of California Inc has achieved several significant milestones. Firstly, the company pioneered and developed Single Molecule, Real-Time (SMRT) DNA sequencing technology, revolutionizing biological research and genomic analysis. Secondly, Pacific Biosciences launched its first commercial instrument, the PacBio RS II System, which enabled long-read sequencing with unmatched accuracy. Furthermore, the company introduced the Sequel System, delivering increased scalability, affordability, and more extensive applications. Pacific Biosciences partnered with various renowned research institutions, industry leaders, and government agencies to advance scientific discovery and genomics research worldwide. These accomplishments have positioned Pacific Biosciences of California Inc as a leading provider of innovative genomic solutions, empowering researchers and scientists in deciphering the complexities of biology.

What is the history and background of the company Pacific Biosciences of California?

Pacific Biosciences of California Inc is a leading biotechnology company headquartered in California. Established in 2004, the company focuses on developing innovative solutions for genetic research and targeted sequencing technologies. Pacific Biosciences of California Inc is known for its state-of-the-art DNA sequencing platforms, enabling an in-depth understanding of complex biological systems. With a strong commitment to advancing scientific knowledge, the company has made significant contributions to various fields, including genomics, personalized medicine, and evolutionary biology. Leveraging cutting-edge technology and a dedicated team of experts, Pacific Biosciences of California Inc continues to drive advancements in genetic research and provide valuable insights into the intricacies of life science.

Who are the main competitors of Pacific Biosciences of California in the market?

The main competitors of Pacific Biosciences of California Inc in the market include Illumina Inc., Thermo Fisher Scientific Inc., and Oxford Nanopore Technologies Ltd.

In which industries is Pacific Biosciences of California primarily active?

Pacific Biosciences of California Inc is primarily active in the biotechnology industry.

What is the business model of Pacific Biosciences of California?

The business model of Pacific Biosciences of California Inc is focused on enabling the use of SMRT Sequencing technology to advance scientific research and genomic understanding. The company develops and sells innovative sequencing systems that provide high-quality genetic data with a wide range of applications in areas such as human genetics, plant and animal sciences, and microbiology. Pacific Biosciences combines its proprietary technology with extensive customer support and collaboration to offer reliable sequencing solutions to academic institutions, government organizations, and pharmaceutical companies worldwide. With a strong emphasis on cutting-edge genomics, Pacific Biosciences aims to drive breakthrough discoveries and contribute to advancements in personalized medicine and agricultural biotechnology.

What is the P/E ratio of Pacific Biosciences of California 2024?

The Pacific Biosciences of California P/E ratio is -1.61.

What is the P/S ratio of Pacific Biosciences of California 2024?

The Pacific Biosciences of California P/S ratio is 2.23.

What is the AlleAktien quality score of Pacific Biosciences of California?

The AlleAktien quality score for Pacific Biosciences of California is 6/10.

What is the revenue of Pacific Biosciences of California 2024?

The expected Pacific Biosciences of California revenue is 183.94 M USD.

How high is the profit of Pacific Biosciences of California 2024?

The expected Pacific Biosciences of California profit is -254.59 M USD.

What is the business model of Pacific Biosciences of California

Pacific Biosciences of California Inc. is a company specializing in the development and marketing of DNA sequencing systems. The company was founded in 2004 and is headquartered in Menlo Park, California. Pacific Biosciences' business model focuses on providing DNA sequencing technologies and services to research institutions, pharmaceutical, and biotech companies. The company offers a portfolio of DNA sequencing systems and services to meet the needs of its customers. The product range primarily includes the SMRT (Single-Molecule, Real-Time) Sequencing System, which can analyze single molecules in real time. The SMRT system enables the detection of DNA methylation patterns, RNA transcript variants, fusion genes, and structural variations that cannot be detected by conventional sequencing methods. In addition, Pacific Biosciences also provides various services to support its customers with DNA sequencing. These include sequencing services, data analysis and reporting, as well as training and technical support. The company also has partnerships with other pharmaceutical and biotech companies to support the development of diagnostics and drugs. However, Pacific Biosciences' business model also faces challenges. The competition in the sequencing industry is strong, with established companies like Illumina and Thermo Fisher already holding a large market share. Additionally, the high costs of the systems and services can deter potential customers. The market for DNA sequencing systems is also closely tied to the research market, which is dependent on household budgets that can fluctuate over time. Nevertheless, Pacific Biosciences has experienced strong growth as more research institutions and pharmaceutical and biotech companies seek more advanced methods of DNA sequencing. In recent years, the company has also formed partnerships with companies like Invitae and Agilent Technologies to expand its presence in the diagnostics industry and provide customers with a more comprehensive solution. In summary, Pacific Biosciences' business model is centered around providing DNA sequencing technologies and services. The company offers a variety of products and services to meet the needs of research institutions and pharmaceutical and biotech companies. Pacific Biosciences' escalation model has firmly established it in the industry, and the company is committed to continuously improving and expanding its offerings to remain at the forefront of DNA sequencing technology.

What is the Pacific Biosciences of California dividend?

Pacific Biosciences of California pays a dividend of 0 USD distributed over payouts per year.

How often does Pacific Biosciences of California pay dividends?

The dividend cannot currently be calculated for Pacific Biosciences of California or the company does not pay out a dividend.

What is the Pacific Biosciences of California ISIN?

The ISIN of Pacific Biosciences of California is US69404D1081.

What is the Pacific Biosciences of California WKN?

The WKN of Pacific Biosciences of California is A1C3EQ.

What is the Pacific Biosciences of California ticker?

The ticker of Pacific Biosciences of California is PACB.

How much dividend does Pacific Biosciences of California pay?

Over the past 12 months, Pacific Biosciences of California paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pacific Biosciences of California is expected to pay a dividend of 0 USD.

What is the dividend yield of Pacific Biosciences of California?

The current dividend yield of Pacific Biosciences of California is .

When does Pacific Biosciences of California pay dividends?

Pacific Biosciences of California pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Pacific Biosciences of California?

Pacific Biosciences of California paid dividends every year for the past 0 years.

What is the dividend of Pacific Biosciences of California?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Pacific Biosciences of California located?

Pacific Biosciences of California is assigned to the 'Health' sector.

Wann musste ich die Aktien von Pacific Biosciences of California kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Pacific Biosciences of California from 7/16/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/16/2024.

When did Pacific Biosciences of California pay the last dividend?

The last dividend was paid out on 7/16/2024.

What was the dividend of Pacific Biosciences of California in the year 2023?

In the year 2023, Pacific Biosciences of California distributed 0 USD as dividends.

In which currency does Pacific Biosciences of California pay out the dividend?

The dividends of Pacific Biosciences of California are distributed in USD.

All fundamentals about Pacific Biosciences of California

Our stock analysis for Pacific Biosciences of California Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pacific Biosciences of California Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.